Dental and Medical Problems
2020, vol. 57, nr 2, April-June, p. 131–136
Publication type: original article
Histopathological alterations of the intrinsic tongue muscles following zoledronic acid treatment in a rat model
Zmiany histopatologiczne wewnętrznych mięśni języka szczura po zastosowaniu kwasu zoledronowego
1 Department of Oral Biology, Faculty of Dentistry, Cairo University, Egypt
Background. Bisphosphonates (BPs) are widely used as anti-bone-resorptive agents. Despite the great benefits of BPs, they may cause local and systemic adverse side effects.
Objectives. The aim of this study was to evaluate the histopathological effect zoledronic acid (ZA), which belongs to BPs, has on the intrinsic tongue muscles in a rat model.
Material and Methods. A total of 30 adult male albino rats were divided into 3 groups (10 rats each): group I served as a control; group II was given an intraperitoneal (i.p.) injection of 0.2 mg/kg of ZA once per week for 3 weeks; and group III received the same dosage of ZA, but for 8 weeks. After the animals were euthanized, the tongue tissue was dissected and examined histologically, histochemically and immunohistochemically.
Results. Histologically, a normal architecture of the muscle fascicles was observed in the control group. Group II showed degenerated muscle fibers with an indistinct sarcolemma. In group III, the muscle fibers were degenerated with severe sarcoplasmic dissolution. The histochemical examination using Masson’s trichrome (MT) demonstrated a significant increase in collagen fibers in groups II and III as compared to the control group. The immunohistochemical results revealed a statistically significantly higher expression of nuclear factor kappa B (NF‑κB) in the ZA-treated groups (II and III) as compared to the control group, with the highest mean value recorded in group III.
Conclusion. Zoledronic acid induced histopathological changes to the intrinsic tongue muscles, and this effect was exaggerated with a longer duration of administration.
zoledronic acid, bisphosphonates, muscle fibers, collagen, rats
kwas zoledronowy, bisfosfoniany, włókna mięśniowe, kolagen, szczury
- Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child. 2005;90(5):494–499.
- Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9(32):2643–2658.
- Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 1996;19(3):281–290.
- Lehenkari PP, Kellinsalmi M, Näpänkangas JP, et al. Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002;61(5):1255–1262.
- Ballantyne E. Bisphosphonates: Possible modes of action and implications for dental implant treatment. A review of the literature. J Gen Pract. 2015;3:192.
- Valdespino V, Tsagozis P, Pisa P. Current perspectives in the treatment of advanced prostate cancer. Med Oncol. 2007;24(3):273–286.
- Coscia M, Quaglino E, Iezzi M, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14(12):2803–2815.
- Ruggiero SL. Bisphosphonate‑related osteonecrosis of the jaw: An overview. Ann N Y Acad Sci. 2011;1218:38–46.
- Allam E, Allen M, Chu TM, Ghoneima A, Jack Windsor L. In vivo effects of zoledronic acid on oral mucosal epithelial cells. Oral Dis. 2011;17(3):291–297.
- Yamada J, Tsuno NH, Kitayama J, et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res. 2009;151(1):115–120.
- Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302(3):1055–1061.
- Pacheco VN, Langie R, Benfica JRD, et al. Nitrogen-containing bisphosphonate therapy – Part II: Assessment of alveolar bone tissue inflammatory response in rats – a blind randomized controlled trial. Int J Exp Pathol. 2018;99(5):258–263.
- Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91(7):1191–1200.
- Kuchay MS, Farooqui KJ, Mithal A. Acute severe diarrhea and hyponatremia after zoledronic acid infusion: An acute phase reaction. Clin Cases Miner Bone Metab. 2017;14(1):101–104.
- Lim SY, Bolster MB. What can we do about musculoskeletal pain from bisphosphonates? Cleve Clin J Med. 2018;85(9):675–678.
- Stål P, Marklund S, Thornell LE, De Paul R, Eriksson PO. Fibre composition of human intrinsic tongue muscles. Cells Tissues Organs. 2003;173(3):147–161.
- Gillett MB, Pradeep KE, Mikhail M. Malacoplakia of the tongue. J Clin Pathol. 2006;59(1):112.
- Pesce C, Pate G, Valente S, Tanzi R. Focal malakoplakia in chronic periapical periodontitis. Histopathology. 1999;34(2):140–143.
- Basso FG, Pansani TN, Soares DG, Cardoso LM, Hebling J, de Souza Costa CA. Influence of bisphosphonates on the adherence and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces. Clin Oral Investig. 2018;22(2):893–900.
- Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–289.
- Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003;191(2–3):159–167.
- Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: Its role in health and disease. J Mol Med (Berl). 2004;82(7):434–448.
- Muratsu D, Yoshiga D, Taketomi T, et al. Zoledronic acid enhances lipopolysaccharide-stimulated proinflammatory reactions through controlled expression of SOCS1 in macrophages. PLoS One. 2013;8(7):e67906.
- Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet Genomics. 2011;21(1):50–53.
- Wang XX, Ying P, Diao F, et al. Altered protein prenylation in Sertoli cells is associated with adult infertility resulting from childhood mumps infection. J Exp Med. 2013;210(8):1559–1574.
- Kumar A, Boriek AM. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: A possible role in Duchenne muscular dystrophy. FASEB J. 2003;17(3):386–396.
- Thoma A, Lightfoot AP. NF‑κB and inflammatory cytokine signaling: Role in skeletal muscle atrophy. Adv Exp Med Biol. 2018;1088:267–279.
- Meinen S, Barzaghi P, Lin S, Lochmüller H, Ruegg MA. Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages. J Cell Biol. 2007;176(7):979–993.
- Lańcut M, Jedrych B, Lis‑Sochocka M, Czerny K. Histological and ultrastructural changes in cross‑striation muscle cells, under the influence of atorvastatin‑reductase HMG‑CoA inhibitor. Ann Univ Mariae Curie Sklodowska Med. 2004;59(2):32–37.
- Gosselin LE, McCormick KM. Targeting the immune system to improve ventilatory function in muscular dystrophy. Med Sci Sports Exerc. 2004;36(1):44–51.